Previous 10 | Next 10 |
Biohaven Pharmaceutical has a significant portfolio of innovative product candidates across neurological and neuropsychiatric diseases. The company's product, NURTEC ODT, is the first and only therapy approved by FDA to both treat and prevent migraine attacks. With new partnership...
Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis PR Newswire Longitudinal medical and prescription claims were used to assess opioid prescriptions and MME's dis...
Biohaven Expands Commitment to Supporting Veterans and Military Through Sole Sponsorship of National Headache Foundation's (NHF) Outreach Program PR Newswire NHF's Veterans/Military Outreach Program aims at raising awareness of migraine in this high-risk population ...
We are initiating coverage of Axsome Therapeutics with a BUY rating, TP of 120 USD. Our enthusiasm revolves around the April 29th PDUFA for AXS-07 targeting migraine, where we believe there is around a ~90% probability of approval (valuation section). We like Axsome Therapeutics' ...
Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal PR Newswire NEW HAVEN, Conn. , April 1, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that data from a Phase 1, sing...
Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases PR Newswire Migraine patients treated with Nurtec ODT had a reduction in...
Glenview Capital Management’s 13F portfolio value decreased from $5.46B to $4.69B this quarter. The number of positions decreased from 59 to 57. They increased Global Payments and Coca Cola Euro Partners while dropping Paramount Global and Takeda. The top three stakes are T...
The outlook for the pharmaceutical and biotech industry is good thanks to resilience versus crises and large macro tailwinds. XBI and many biotech names have sold off a lot over the last year. The ETF is now trading lower than before the pandemic. XBI's approach is different from ...
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Q4 2021 Earnings Conference Call February 25, 2022 8:30 AM ET Company Participants Caroline Dircks – Vice President, Corporate Operations Vlad Coric – Chief Executive Officer Matthew Buten – Chief Financial Officer BJ Jo...
The following slide deck was published by Biohaven Pharmaceutical Holding Company Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Biohaven Pharmaceutical Holding Company Ltd. 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-24 06:30:09 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for BHVN on July 24, 2024 04:48AM ET. BHVN was trading at $37.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy reco...
2024-07-24 06:00:03 ET Terence Flynn from Morgan Stanley issued a price target of $58.00 for BHVN on 2024-07-24 04:48:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $37.81. The overall price target consensus is at $4...
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...